Our Team

The Fibronostic Team Bios
brettbiopic.jpg
BRETT GIFFIN
CEO

Brett joined Fibronostics as CEO in September of 2017, after serving 2 ½ years as President & CEO of 3si Systems, an IT-based healthcare technology company. Brett has more than 30 years of executive experience in a variety of general and commercial management roles in large, medium, and small healthcare companies. He has extensive experience in P&L management, sales and marketing leadership, strategic planning, product launches, product development, and business development on a global level.

Prior to 3si Systems, Brett was the Chief Commercial Officer of Accriva Diagnostics, a Warburg Pincus portfolio company, formed in 2013 through the merger of International Technidyne Corporation (ITC) and Accumetrics. In his almost 8 years of executive leadership roles with Accriva/ITC Brett led the company through greater than market revenue growth, successfully managed the acquisition of Accumetrics, and led the global commercial integration of the ITC and Accumetrics companies. Brett played a key leadership role in the divestiture of ITC from publicly-traded Thoratec Corporation and succeeding sale of the company to Warburg Pincus in 2010.

Prior to Accriva/ITC, Brett served in leadership roles with Drager Medical as Vice President of Marketing, iDEV Technologies as National Sales Director, Vice President of Sales & Marketing at Datascope Corporation , Vice President of Marketing at Mallinckrodt Medical, International Marketing Manager at Boston Scientific, and a variety of positions in marketing and sales management over a 10-year period with Johnson & Johnson Medical.

Brett began his career as a US Army Officer, attained the final rank of Captain, and served in Panama and Latin America. He has a B.A. degree from Christopher Newport University, is a Distinguished Military Graduate from the College of William & Mary, and holds an M.A. in Business Management from the University of Phoenix.

gregauda.jpg
GREG AUDA
CCO
Joined Fibronostics in February of 2018 as Chief Commercial Officer. Greg is a Medical Device executive with over 25 years of experience and extensive leadership roles in: Business Development, Strategic Marketing, Channel Development, Product launches, International Marketing, Strategic Account Management, Synergy Development and Sales Management, in both large and small companies.

Before joining Fibronostics he worked in leadership roles with 3si, a startup Healthcare IT company dedicated to patient safety in surgery; and most recently held a senior position with FlexPro, a project management firm in the life science space where he ran Business Development and Marketing.

Prior to those efforts Greg held several leadership positions at Johnson & Johnson’s Depuy Synthes division, including Account Director where he was responsible for Strategic Account Management at regional IDNs. In addition, Greg established and led the team that set up the Strategic Account effort for the Synthes CMF division.

The majority of Greg’s time at Depuy Synthes, was in the position of Director of Business Development where he was responsible for all aspects of the Business Development and Channel Development process for the CMF Division. He was actively involved in the acquisition and integration of J&J and Synthes, co leading a team to gain incremental value from the two organizations.

Prior to J&J, Greg ran the Marketing team at Accellent. He was part of the team that completed several acquisitions and ultimately a successful exit for the company, completing the sale of Accellent to KKR.  In addition, Greg held several leadership positions in smaller organizations including Hemametrics, where he and his team ran Sales and Marketing efforts.

His earlier experience was with J&J in the Codman Neuro Surgery Division.  During that time, he held a variety of sales & marketing roles, including Director of International Marketing and Director of Marketing for the Surgical Instrument franchise, where he and his team, maintained and grew revenue and profitability in a rapidly commoditizing market. Before that he was in product management, sales management and field sales.

Greg is a graduate of Gettysburg College in Gettysburg PA, where he earned a BA in Business Administration. He has worked with Habitat for Humanity and served on a Township Public Safety Committee and Beach Preservation Committee. He has guest lectured at Tulane University; School of Science and Engineering, addressing their Bio Medical Entrepreneur program on challenges in Orthopedics and career ethics.
hawleybiopic.jpg
Hawley K. Linke, PhD
SENIOR DIRECTOR, SCIENTIFIC AFFAIRS
In 2014, after 25 years with the global healthcare and research leader, Abbott Laboratories, Hawley engaged with Fibronostics’ parent company, SPRIM, as a Consultant and Advisor for Research and Clinical Services to the SII group in Orlando, FL.  She joined the leadership team of Fibronostics in late 2017 as the Senior Director for Scientific Affairs.  

Hawley’s Abbott experience included seven years with Abbott Diagnostics, Hepatitis-AIDS department as a Sr. Scientist and group leader of the molecular biology team charged with identifying the agent for so-called non-A, non-B hepatitis (now, HCV).  Her investigations during that time also involved establishing a relationship between HCV infection and hepatocellular carcinoma (HCC) in a large primate model.

In the early 1990’s Hawley brought molecular biology to Abbott Nutrition (formerly Ross Laboratories).  During that time her contributions ranged from running a laboratory that developed genetically engineered novel molecules in production quantities suitable as the basic protein source for infants and children with inborn errors of metabolism; to creating transgenic mammals whose milk contained high levels (grams/liter) of an essential human hormone found naturally in breastmilk.  Beyond molecular biology she has led clinical studies in infant nutrition and supported an FDA submission that delivered the first ever US claim for medical efficacy in standard infant formula.  Other successful clinical outcomes and technology targets included allergy, otitis media, infant respiratory infections, human milk oligosaccharides, gastrointestinal symptom relief, probiotic modulation, necrotizing enterocolitis diagnostics for the NICU, metabolomics profiling, and human microbiome implications for nutrition strategies. She also has experience with prion agents and the CNS virus associated with progressive multifocal leukoencephalopathy (PML).  

Hawley received her AB degree in Zoology from San Diego State University; a doctorate in Molecular Biology for the University of California, Los Angeles; and served as a post-doctoral fellow in the Department of Pathology at the Stanford University School of Medicine.
rodneybiopic.jpg
RODNEY CHEUNG
CIO
High-performance CIO/CTO and visionary with over 28 years of strategically using of innovative technologies for start-up ventures through to global financial organizations to achieve business objectives. Keys to success include in-depth technology portfolio deployment expertise and ability to form highly collaborative partnerships with the business to further its objectives.

A proactive learner named as one of the Top 50 Best and Brightest Worldwide Executive MBA graduates in 2017  for the University of Toronto (U of T) Masters in Business Administration (MBA) along with University of Waterloo Systems Design Engineering degree. Real world experience in technology infrastructure and application deployment and proven track record of delivery on objectives.Leader in developing massively scalable technology-based startup ventures with equity value creation with focus on Machine Learning (ML) / Artificial Intelligence (AI), Virtual and Augmented Reality (VR/AR), and the Internet of Everything (IoE/IoT) at the U of T Rotman Technology based Creative Destruction Lab (CDL).

About FIBRONOSTICS

We are a team of life science experts, physicians, mathematicians, health IT professionals and software architects.